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Abstract
Introduction
Hydrops fetalis (HF) is a life-threatening condition in which a fetus has an abnormal collection of fluid in
the tissue around the lungs, heart, abdomen, or under the skin. Based on its pathophysiology, it is classified
into immune and non-immune types. With the widespread use of anti-D immunoglobulin, non-immune HF
has become more common, with an incidence of one in 1,700-3,000 live births. A multitude of fetal diseases
with various causes can lead to non-immune HF. Due to the recent advances in prenatal diagnostic and
therapeutic interventions together with improved neonatal intensive care, the diagnosis and subsequent
management of HF have been refined. However, HF is still associated with a high mortality rate. A recent
assessment of the literature found that there is a lack of data on prognostic variables in neonates with HF
from low- and middle-income countries. In light of this, we sought to establish the etiologic causes,
predictors of mortality, and eventual fate of newborns born non-immune HF at the Aga Khan University
Hospital, Karachi during the 10-year period spanning January 2009-December 2019 in this retrospective
analysis.
Methodology
For this study, we collected data from the computerized database and patient record files at the hospital on
all infants with non-immune HF. Demographic data, postnatal interventions, clinical and laboratory
findings, outcomes, and the results of comparison between HF patients who died and those who survived
were analyzed.
Results
The incidence of non-immune HF at our hospital was 0.62/1,000 live births during the period under study,
with 33 newborn babies diagnosed with non-immune HF from a total of 53,033 live-born deliveries. An
etiologic factor was discovered in 17 (51.5%) neonates with non-immune HF while 16 (48.4%) were classified
as those with unidentified etiology. The most common causes were cardiovascular and genetic syndromes,
which resulted in 100% mortality. The overall mortality rate was 67%. The need for mechanical ventilation,
surfactant therapy, and prolonged hospitalization were identified as independent risk factors of mortality.
Conclusion
Our study proves that the need for mechanical ventilation [moderate to severe hypoxic respiratory failure
(HRF)] and prolonged hospitalization are strong predictors of poor outcomes in neonates with non-immune
HF. Therefore, severe hydrops causing significant mortality can be anticipated based on the patients'
respiratory status and the need for escalated oxygen support.
Categories: Genetics, Pediatrics, Other
Keywords: hydrops fetalis, pleural effusion, neonate, ascites, generalized anasarca
Introduction
Hydrops fetalis (HF) is a well-recognized fetal condition, and it is defined as the presence of extracellular
fluid either in at least two fetal body compartments or one body compartment in the presence of skin edema
(>5-mm thickness). Ascites, pleural and pericardial effusions, and anasarca are all symptoms of pathologic
buildup of extracellular fluid in the skin or bodily compartments. Most instances of HF have a non-immune
etiology due to the decline in rhesus isoimmunization. According to the literature, non-immune HF accounts
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for roughly 76-87% of all cases of HF, while its incidence varies from one in 1,700-3,000 live births [1-3]. A
significant number of fatal diseases with various causes can lead to non-immune HF. The principal
pathophysiology of non-immune HF is consistent with abnormal fluid transportation between plasma and
tissues, which are either geared by an increase in hydrostatic pressure and capillary permeability or the
reduction of the plasma osmotic pressure or lymphatic flow [4]. Recent breakthroughs in prenatal diagnostic
and therapeutic measures, as well as enhanced postnatal intensive care, have led to significant advances in
the diagnosis and subsequent treatment of non-immune HF. On the other hand, the mortality rate is still
very high [5-6]. Recent research demonstrates that there is a lack of evidence on prognostic variables in
newborn babies with non-immune HF, which is mostly dependent on the underlying etiology [7-10].
In this study, we aimed to determine the etiologic factors, the predictors of mortality, and the eventual
outcomes in newborns born with non-immune HF at a tertiary care referral center in Pakistan over a period
of 10 years.
Materials And Methods
This was a retrospective hospital study carried out at the neonatal intensive care unit (NICU) of the Agha
Khan University Hospital in Karachi, Pakistan on newborns born with non-immune HF at the facility during
the 10-year period spanning from January 2009 to December 2019. Institutional Ethics Review Committee
(IERC) permission was obtained, with an issued certificate number (2020-5270-13945). The study only
included live-born infants who survived in the delivery room with or without the requirement for neonatal
resuscitation. Our non-immune HF cohort was defined as those having generalized skin edema with
pathologic collection of serous fluid in one or more fetal body compartments or the presence of extracellular
fluid in at least two fetal body compartments. Immune HF was classified based on clinical and laboratory
results (maternal and neonatal blood group, evidence of hemolysis, and Coombs test). Postnatal diagnostic
and therapeutic interventions, demographic data, APGAR score at the fifth minute, postnatal therapies such
as mechanical ventilation and surfactant therapy, causative factors of non-immune HF, and mortality were
all evaluated for each neonate.
All categorical variables such as gender, consanguinity, diagnosis, and mode of delivery were presented as
numbers and percentages. Continuous variables such as gestational age, weight, and height were expressed
as mean ± standard deviation (SD), while the duration of mechanical ventilation and hospitalization were
presented as median. The parametric test was applied when data were normally distributed whereas non-
parametric tests were applied when data were skewed. The Kolmogorov-Smirnov test was used to check the
assumption of normal distribution. The chi-square/Fisher's exact test was applied according to whether the
cell expected frequency was smaller than 5, and it was also applied to determine the significant association
between categorical variables. The unadjusted odds ratio was calculated to find out the association and
potential risk factors related to mortality. Multivariate logistic regression analysis by backward elimination
method was applied to determine the most significant risk factors/predictors of the risk of mortality. Due to
the small sample size, we could not attain variables in the final model at a 5% level of significance.
Therefore, we attained variables at a 10% level of significance. All data were analyzed using Stata version 16
(StataCorp, College Station, TX).
As per our NICU policy, a baseline workup, including complete blood count with peripheral smear, Coombs
test and TORCH [toxoplasmosis, rubella cytomegalovirus (CMV), herpes simplex, and HIV] screening,
echocardiography, ultrasound, and X-ray chest and abdomen, was performed for all neonates with HF.
For possible lymphatic dysplasia, lymphoscintigraphy and biochemical investigation (lipid profile) of ascitic
or pleural fluid were carried out. Suspected inherited metabolic disorders were screened with plasma
ammonia, serum lactate, urine organic acid, and plasma amino acid analysis. Toxoplasmosis, rubella, CMV,
and herpes simplex were all tested for intrauterine illnesses in all of the babies. In a small number of
undiagnosed instances of non-immune HF, modest genetic testing in the form of karyotyping may be
possible.
The clinical and demographic characteristics of infants with non-immune HF who died and those who
survived were compared. All indicators strongly associated with mortality were incorporated in stepwise
multiple logistic regression models to establish independent predictors of death.
Results
During the 10-year study period, 33 cases of non-immune HF were detected in our tertiary care perinatal
referral center from 53,033 live-born neonates, with an incidence of 0.62/1,000 live births.
The median gestational age was 35 years (range: 32-36 years), whereas the mean birth weight was 2.34 ± 0.72
kg. Seventeen (52%) were products of consanguineous marriage. Prenatal diagnosis of non-immune HF was
made in 31 (94%) neonates. Regarding the postnatal procedures, 14 (42%) patients had thoracocentesis,
three (9%) had a blood transfusion, and only one (3%) had paracentesis. Twenty-four (73%) neonates
presented with effusion in two or more serous cavities, five (15%) with pleural effusion, and four (12%) with
ascites only. At birth, 22 (67%) neonates required aggressive resuscitation either by positive pressure
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ventilation (PPV), chest compression (CC), or a lifesaving drug (epinephrine). Twenty-two (67%) infants
needed mechanical ventilation while 21 (64%) of them had moderate to severe hypoxic respiratory failure
(HRF) with an oxygenation index (OI) of >14. Among the total 33 total cases, 22 (67%) died while 11 (33%)
survived. The demographic and clinical profiles of neonates with non-immune HF are shown in Table 1.
Characteristics Values
Gender (male/female), n (%) 20/13 (61%/39%)
Gestational age (weeks), median (range) 35 (32–36)
Weight (kg), mean ± SD 2.34 ± 0.72
Height (cm), mean ± SD 45.03 ± 4.96
FOC (cm), mean ± SD 32.98 ± 2.62
Place of delivery (inborn/outborn), n (%) 30/3 (91%/9%)
Consanguinity, n (%) 17 (52%)
Prenatal diagnosis of HF, n (%) 31 (94%)
Postnatal diagnostic and therapeutic procedure, n (%)
Thoracocentesis 14 (42%)
Blood transfusion 3 (9%)
Paracentesis 1 (3%)
Mode of delivery (LSCS/SVD), n (%) 29/4 (88%/12%)
APGAR score (5 minutes), mean (range) 7 (3–9)
Resuscitation required at birth (PPV ± CC ± drug), n (%) 22 (67%)
Affected compartments in HF, n (%)
Ascites 4 (12%)
Pleural effusion 5 (15%)
Two or more serous cavity effusion 24 (73%)
Hypoxic respiratory failure (moderate to severe OI >14), n (%) 21 (64%)
Need for mechanical ventilation, n (%) 22 (67%)
Need for HFOV, n (%) 7 (21%)
Need for surfactant, n (%) 3 (9%)
Pneumothorax, n (%) 4 (12%)
Duration of mechanical ventilation (days), median (range) 3 (1–7)
Duration of hospitalization (days), median (range) 6 (1–13)
Died, n (%) 22 (67%)
Survived, n (%) 11 (33%)
TABLE 1: Demographic and clinical profile of neonates with non-immune hydrops fetalis (n=33)
SD: standard deviation; FOC: fronto-occipital circumference; HF: hydrops fetalis; LSCS: lower segment cesarean section; SVD: spontaneous
vaginal delivery; PPV: positive pressure ventilation; CC: chest compression; OI: oxygenation index; HFOV: high-frequency oscillatory ventilation
Among the neonates with non-immune HF, a credible cause could be identified in 17 (51.5%) cases.
Cardiovascular disease was the most commonly found (five, 15.1%) underlying cause in neonates with non-
immune HF, followed by genetic syndromes (four, 12.1%), and both had 100% mortality as shown in Table 2.
There were two cases of severe ventricular dysfunction, one case of hypertrophic cardiomyopathy, one case
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of dilated cardiomyopathy, and one case of complicated heart disease among the five neonates with
cardiovascular diseases. Two of the cases with genetic syndromes had Down syndrome, one had Edwards'
syndrome, and one had an unclassified syndrome. Among other identifiable causes, two (6%) had a placental
disorder (twin-twin transfusion syndrome) and two (6%) had a renal disorder (posterior urethral valve with
vesicoureteral reflux). There was one case (3%) each of hematological (transient abnormal myelopoiesis),
lymphatic (chylothorax), infective (congenital rubella syndrome), and neurological disorders (Arnold Chiari
malformation II). All of these aforementioned cases survived in our study. However, only six of the 16
(48.4%) cases with unknown etiology survived, while the other 10 died.
Determinants N (%)
Cardiovascular diseases 5 (15.1)
Hypertrophic cardiomyopathy 1 (3)
Dilated cardiomyopathy 1 (3)
Severe ventricular dysfunction 2 (6)
Complex heart disease (PDA + VSD + ASD + CoA) 1 (3)
Genetic syndrome 4 (12.1)
Down syndrome 2 (6)
Edwards' syndrome 1 (3)
Unclassified syndrome 1 (3)
Lymphatic disorder (chylothorax) 1 (3)
Hematologic disease (transient abnormal myelopoiesis) 1 (3)
Placental disorders (twin-twin transfusion syndrome) 2 (6)
Renal disorders (posterior urethral valve with vesicoureteral reflux) 2 (6)
Neurologic malformation (Arnold Chiari malformation II) 1 (3)
Infections (congenital rubella) 1 (3)
Unidentified etiology 16 (48.4)
TABLE 2: Etiology of non-immune hydrops fetalis (n=33)
PDA: patent ductus arteriosus; VSD: ventricular septal defect; ASD: atrial septal defect; CoA: coarctation of the aorta
When comparing newborns who survived with those who died, neonates who died had significantly higher
requirements for mechanical ventilation, moderate to severe HRF (OI >14), and prolonged hospitalization
(p=0.027, 0.001, and 0.048, respectively). The effects of gestational age and the presence of two or more
serous cavity effusions were not statistically significant in our study (Table 3).
On stepwise multiple logistic regression analysis, the need for mechanical ventilation, prolonged





Died (n=22) Survived (n=11)
Gender
Male, n (%) 12 (55%) 8 (73%)
0.391
Female, n (%) 10 (45%) 3 (27%)
Gestational age (weeks) Mean ± SD; median (IQR) 33.91 ± 3.13 34 (33–36) 0.931
Place of delivery
Inborn, n (%) 20 (91%) 10 (91%)
0.999
Outborn, n (%) 1 (9%) 2 (9%)
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Consanguinity
Yes, n (%) 13 (59%) 4 (36%)
0.224
No, n (%) 9 (41%) 7 (64%)
Diagnosis
Prenatal, n (%) 21 (95%) 10 (91%)
0.631
Postnatal, n (%) 1 (5%) 1 (9%)
Postnatal diagnostic and therapeutic procedure
Thoracocentesis, n (%) 10 (45%) 4 (36%) 0.782
Blood transfusion, n (%) 1 (5%) 2 (18%) 0.301
Paracentesis, n (%) 1 (5%) 0 (0.0%) -
Mode of delivery
LSCS, n (%) 19 (86%) 10 (91%)
0.999
SVD, n (%) 3 (14%) 1 (9%)
APGAR score (5 minutes) Mean ± SD 6.13 ± 2.45 7.90 ± 1.91 0.081
Resuscitation required at birth
Yes, n (%) 18 (82%) 4 (36%)
0.014
No, n (%) 4 (18%) 7 (64%)
Affected compartments in HF
Ascites, n (%) 3 (14%) 1 (9%) 0.742
Pleural effusion 3 (14%) 2 (18%) 0.776
Two or more serous cavity effusion, n (%) 16 (73%) 8 (73%) -
Moderate to severe HRF (OI >14)
Yes, n (%) 19 (86%) 2 (18%)
0.001*
No, n (%) 3 (14%) 9 (82%)
Need for mechanical ventilation
Yes, n (%) 17 (77%) 5 (45%)
0.027*
No, n (%) 5 (23%) 6 (55%)
Need for HFOV
Yes, n (%) 6 (47%) 1 (9%)
0.252
No, n (%) 16 (73%) 10 (91%)
Need for surfactant
Yes, n (%) 1 (5%) 2 (18%)
0.232
No, n (%) 21 (95%) 9 (82%)
Pneumothorax
Yes, n (%) 3 (14%) 1 (9%)
0.780
No, n (%) 19 (86%) 10 (91%)
Duration of mechanical ventilation (days) Median (IQR) 1.50 (1.00–6.50) 7.00 (7.00–16.00) 0.073
Duration of hospitalization (days) Median (IQR) 1.00 (1.00–7.00) 13.00 (10.00–16.00) 0.048*
TABLE 3: Effect and association of study outcomes and factors affecting the mortality of the
patients
*Statistically significant
HF: hydrops fetalis; HRF: hypoxic respiratory failure; OI: oxygenation index; HFOV: high-frequency oscillatory ventilation; IQR: interquartile range;
SD: standard deviation
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Factors AOR [95% CI] P-value
Need for mechanical ventilation 16.83 [1.37–206.09] 0.027*
Need for surfactant 0.04 [0.001–1.10] 0.057
Duration of hospitalization 0.89 [0.79–0.99] 0.038*
TABLE 4: Identification of predictors of mortality in non-immune hydrops fetalis by multiple
logistics regression analysis
*Statistically significant
AOR: adjusted odds ratio; CI: confidence interval
Discussion
According to recent data from affluent countries, the majority of neonates with HF have non-immune HF,
with the prevalence of immune HF reduced to 10%. This has been made possible because of the use of anti-D
immunoglobulin prophylaxis, intrauterine transfusions, and rigorous fetal observation of rhesus
isoimmunized pregnancies [5]. However, the incidence of immune HF is still considered to be high in lower-
middle-income countries (LMICs), but our findings contradict earlier studies, as most of the cases we found
in our study had non-immune HF [11]. The standardized quality care in our tertiary care facility and
increased awareness of anti-D prophylaxis may explain these findings.
Many pregnancies with immune HF and non-immune HF are referred to our hospital, which is a tertiary
care, perinatal referral center for high-risk pregnancies, from all across the country. Because the majority of
these pregnant women are referred late in their pregnancy, diagnostic and therapeutic options are often
limited. Furthermore, a lack of diagnostic and therapeutic fetal interventions in our setting is thought to be
a major contributor to increased mortality in newborns with non-immune HF. The incidence of non-
immune HF varies greatly in the literature, ranging from 0.3/1,000 to 2.4/1,000 live births [12,13]. In our
study, the incidence of non-immune HF was 0.62/1000 live births, which is within the range of previous
research.
The two most common diagnoses associated with non-immune HF in our study were cardiovascular and
genetic syndromes. The prognosis was not favorable in all nine neonates with these conditions, including
five (15.1%) with structural cardiovascular anomalies and four (12.1%) with genetic syndromes, as all of
them died. Other significant causes included placental (twin-twin transfusion syndrome), lymphatic
(chylothorax), renal (posterior urethral valve), infectious (congenital rubella), hematological (transient
abnormal myelopoiesis), and neurologic causes (Arnold Chiari malformation II).
As per the recent studies, there is significant variability with respect to unidentified cases in non-immune
HF, ranging from 4-60%. It depends primarily on the availability of resources required for extensive workup
in diagnosing non-immune HF [3,14,15] In our study, we found a large number of cases (16, 48%) classified
as those with unidentified etiology. This may be due to the limitation of diagnostic facilities available in our
setup. Another explanation of the high occurrence of idiopathic reasons may be the limited amount of time
available to reach an exact diagnosis, as the majority of newborns with non-immune HF died during the first
week of life. Furthermore, the lack of postmortem examinations for idiopathic non-immune HF cases added
to the difficulty in determining the cause. Rodrguez et al. have verified this, with postmortem investigation
confirming the cause of HF in 51 stillborn fetuses, which amounted to 92% of the cases.
In the literature, the incidence of inborn errors of metabolism (IEM) has been calculated to be 1-2% of all
non-immune HF [1]. Although we could not document any case with IEM, we assume the incidence may be
high due to the highly prevalent practice of consanguineous marriages in Pakistan.
Studies have revealed several postnatal prognostic indicators in infants with HF [6,10,16,17]. Prenatal HF
diagnosis, gestational age, first- and fifth-minute APGAR scores, advanced resuscitation, two or more serous
cavity effusions, pleural effusion, and the need for thoracentesis are factors that should be taken into
account.
In various studies, gestational age at delivery and two or more serous compartment effusion were found to be
important prognostic factors [16,18]. However, these were not found to be statistically significant in our
study. This may be attributed to the small sample size of our study. Unlike other reported studies, the need
for mechanical ventilation required for HRF and prolonged hospitalization were identified as independent
predictors of mortality in our study.
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Previously, early delivery for the fetus with HF was associated with favorable outcomes [19]. This has been
nullified by a recent publication of large multicenter data, showing a clear association between prematurity
and poor outcomes, which can be rationalized with established complications of prematurity. Prolonging the
pregnancy with adequate tocolysis, antenatal steroids, and close fetal surveillance is the right approach in
these circumstances. However, the administration of antenatal steroids does not influence the overall
survival in a fetus with HF [6,20].
Neonates with inadequate response to resuscitation in the delivery room have been associated with
increased mortality in the previously published literature [6,16]. These findings are in line with our research,
which found that fatal cases necessitated extensive and advanced resuscitation in the delivery room and had
considerably low APGAR scores in the first minute.
Rustico et al. have shown in their study that intrauterine pleural drainage may improve the outcomes in
fetuses with persistent pleural effusion [21]. This prevents fatal complications associated with pulmonary
hypoplasia by decompressing the lungs and heart and thereby providing the optimum chance for the fetus to
survive. It is assumed that thoracentesis alone is of limited usefulness since pleural fluid reaccumulates
within seven days of the surgery. As a result, it was established that thoracoamniotic shunting may enhance
survival rates, particularly in fetuses with quickly reaccumulating effusion [9]. We were unable to execute
any of these intrauterine operations due to a lack of resources and experience.
Conclusions
Although the incidence of immune HF has significantly decreased with the widespread use of anti-D
immunoglobulins, non-immune HF is still associated with significant mortality. The need for mechanical
ventilation (moderate to severe HRF) and prolonged hospitalization are strong predictors of poor outcomes
in neonates with non-immune HF. Therefore, severe hydrops causing significant mortality can be
anticipated based on the patients' respiratory status and the need for escalated oxygen support.
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